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Abstract
Background: Spinal cord injury (SCI) usually causes a devastating lifelong disability for patients. After a traumatic
lesion, disruption of the blood-spinal cord barrier induces the infiltration of macrophages into the lesion site and
the activation of resident glial cells, which release cytokines and chemokines. These events result in a persistent
inflammation, which has both detrimental and beneficial effects, but eventually limits functional recovery and
contributes to the appearance of neuropathic pain. Bromodomain and extra-terminal domain (BET) proteins are
epigenetic readers that regulate the expression of inflammatory genes by interacting with acetylated lysine
residues. While BET inhibitors are a promising therapeutic strategy for cancer, little is known about their implication
after SCI. Thus, the current study was aimed to investigate the anti-inflammatory role of BET inhibitors in this
pathologic condition.
Methods: We evaluated the effectiveness of the BET inhibitor JQ1 to modify macrophage reactivity in vitro and to
modulate inflammation in a SCI mice model. We analyzed the effects of BET inhibition in pro-inflammatory and
anti-inflammatory cytokine production in vitro and in vivo. We determined the effectiveness of BET inhibition in
tissue sparing, inflammation, neuronal protection, and behavioral outcome after SCI.
Results: We have found that the BET inhibitor JQ1 reduced the levels of pro-inflammatory mediators and increased
the expression of anti-inflammatory cytokines. A prolonged treatment with JQ1 also decreased reactivity of
microglia/macrophages, enhanced neuroprotection and functional recovery, and acutely reduced neuropathic pain
after SCI.
Conclusions: BET protein inhibition is an effective treatment to regulate cytokine production and promote
neuroprotection after SCI. These novel results demonstrate for the first time that targeting BET proteins is an
encouraging approach for SCI repair and a potential strategy to treat other inflammatory pathologies.
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Background
Spinal cord injury (SCI) commonly causes lifelong disabil-
ity that reduces the quality of life and increases morbidity
for the affected patients [1, 2]. Direct consequences of the
injury are the loss of motor, sensory and autonomic func-
tions, producing paralysis, anesthesia, and dysautonomia.
Besides, neuropathic pain arises in many cases, further re-
ducing the quality of life of SCI patients [3]. To date, there
are no effective treatments available [2]. Thus, it is import-
ant to develop new therapeutic strategies to alleviate this
harmful condition.
SCI courses with an inflammatory response that com-
prises mainly microglia and blood-derived macrophages
[4, 5]. Both immune cells induce and magnify the im-
mune response by secreting inflammatory molecules and
influencing glial cells including astrocytes, oligodendro-
cytes, and microglia [6]. Thus, the reaction of the im-
mune system induces a feed-forward response that
produces a persistent pro-inflammatory microenviron-
ment, which contributes to cell death and glial scar
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formation [2, 7]. Secreted pro-inflammatory cytokines
(such as IL-1β, IL-6, TNF-α), as well as cytotoxic factors,
including reactive oxygen and nitrogen species, contrib-
ute to enhance inflammation by recruiting inflammatory
cells to clear debris at the injury area [8], but have the
potential to cause toxicity and increase tissue damage [5,
6, 9, 10]. In addition, the persistent release of these pro-
inflammatory modulators plays a critical role in the in-
duction and maintenance of neuropathic pain [11]. In
contrast, anti-inflammatory cytokines, such as IL-4, IL-
10, and IL-13, help to suppress inflammation by redu-
cing pro-inflammatory cytokine/chemokine production
and contributing to wound healing and tissue remodel-
ing [9, 10, 12].
Bromodomain and extra-terminal domain (BET) pro-
teins belong to the reader family. BET proteins are char-
acterized by the presence of two tandem bromodomains
(BD1 and BD2) and an extra-terminal domain (ET),
which are critical for their function [13, 14]. These pro-
teins bind to acetylated lysine residues in both histone
and non-histone proteins to recruit transcriptional com-
plexes and thus regulate gene expression. As a result,
genes related to proliferation and inflammation are
expressed [13–15]. BET family includes BRD2, BRD3,
BRD4, and BRDT, and among them, BRD4 seem to be
the main responsible for pro-inflammatory gene expres-
sion by interacting with the acetylated lysine-310 at the
p65 transactivation domain of NF-kB [14, 16]. Taking to-
gether, the inhibition of this epigenetic phenomenon is a
promising target to control the inflammatory process.
Given the importance of BET proteins in inflamma-
tion, we hypothesized that these epigenetic mediators
might be a therapeutic target after SCI. We used the
BET inhibitor JQ1 and analyzed the effects after SCI.
We observed that JQ1 produced a decrease of pro-
inflammatory and an increase of anti-inflammatory cyto-
kine expression acutely after SCI. We found that pro-
longed treatment with JQ1 reduced inflammatory
response, increased neuroprotection, and enhanced
functional outcome after SCI. Overall, the results of the
present study indicate that BET proteins are a thera-
peutic target after SCI.
Materials and methods
Spinal cord injury
All experimental procedures were approved by the
Universitat Autònoma de Barcelona Animal Experimentation
Ethical Committee (CEEAH 1188R3-DMAH 6131)
and followed the European Communities Council
Directive 2010/63/EU. A total of 72 8-week-old fe-
male C57BL/6 mice were used for all the procedures
and randomly divided into three groups depending on
the experimental design. General anesthesia was in-
duced by an intraperitoneal injection (i.p.) of a
ketamine (90 mg/kg), xylazine (10 mg/kg), and saline
mixture. After laminectomy, a moderate contusion
was performed to the exposed spinal cord at T11
using the Infinite Horizon Impactor device (60 kDyn,
tissue displacement between 450–600 μm). Animals
received a i.p. dose of 30 mg/kg JQ1 diluted in 5%
DMSO and 5% Tween-80 in saline 2 h post-operation
and daily onwards until specified. Vehicle-treated ani-
mals received only the vehicle solution. Sham mice
underwent the same surgery except the contusion
injury.
BMDM culture
Bone marrow-derived macrophages (BMDMs) were ob-
tained from mouse femurs following a specific isolating
protocol [17]. Briefly, femurs from 8-week-old C57BL/6
mice were cut in a sterile glass and the bone marrow
cavity was flushed out with chilled PBS using 10-ml syr-
inge with 25-G needle. Once the cells were isolated and
centrifuged at 500×g, cells were cultured in DMEM/F-12
medium containing HEPES, 1% 200mM L-glutamine,
10% fetal bovine serum, and 1% penicillin/streptomycin.
In addition, to initiate macrophage differentiation, the
medium was supplemented with 10 ng/ml of macro-
phage colony-stimulating factor (M-CSF; Stanley) for 9–
10 days. During differentiation, the medium was replaced
every 3 days to eliminate contaminating non-adherent
cells. After the differentiation phase, adherent BMDMs
were seeded at a density of 0.3 × 106 cells/well in two
different 6-well plates containing the medium above
mentioned.
At days 9 and 10, DMSO (0.001%), JQ1 (1 μM), or LPS
(100 ng/ml) alone or a combination of JQ1 and LPS was
added to the cultures. First, cells were treated with 100
ng/ml of LPS to initiate the inflammatory response dur-
ing 1 h. Then, either DMSO or 1 μM JQ1 was added for
2 h. Finally, cells were collected for RNA extraction.
RNA isolation, RNA reverse transcription, and RT-qPCR
For in vitro analysis, RNA was extracted using the
RNeasy Micro Kit (QIAGEN) according to the manufac-
turer’s recommendations. For in vivo analysis, adult mice
were perfused with sterile saline 4 h (n = 24) or 4 days
post-SCI (n = 14). Then, a 4-mm-long segment around
the SCI epicenter was removed and snap-frozen. Tissue
was homogenized with QIAzol lysis reagent (QIAGEN),
and RNA was extracted using the RNeasy Mini Kit
(QIAGEN) following the manufacturer’s guidelines.
RNA was quantified with a spectrophotometer (Nano-
Drop Technologies) and reverse-transcribed using an
Applied Biosystems kit (Thermo Fisher Scientific). Then,
the expression of target sequences was quantified by RT-
qPCR using SYBR ® Green QPCR Master Mix (Agilent
Technologies) and the corresponding primers (Table 1).
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a housekeeping gene.
Cytokine protein expression
Adult female C57/Bl6 mice were perfused with sterile
saline and a 5-mm-long segment of sham or the con-
tused spinal cord was collected at 4 and 72 h after SCI
(n = 3 per group and time point) and snap-frozen. The
spinal cords were homogenized, and protein concentra-
tion was determined using the DC Protein Assay (Bio-
Rad). Samples were concentrated to 4 mg/ml using
MicroCon centrifugation filters (Millipore) to ensure
equal amounts of protein. Cytokine protein levels were
then analyzed using the Milliplex MAP Mouse Cyto-
kine/Chemokine magnetic bead panel (Millipore) on a
Luminex (Millipore) as per the manufacturers’ protocol.
Functional assessment
Locomotion recovery was evaluated in an open-field
test using the 9-point Basso Mouse Scale (BMS) at 3,
7, 10, 14, 21, and 28 days post-operation [18]. This
scale ranges from 0, indicating complete paralysis, to
9, indicating normal movement of the hind limbs.
The analysis was carried out by two researchers
which strictly followed blinding procedures to deter-
mine the score for each animal. To evaluate neuro-
pathic pain, mechanical and thermal algesimetry tests
were performed. Mechanical nociception was mea-
sured once a week (at 7, 14, 21, and 28 days post-
operation) by an electronic Randall-Selitto test [19].
Briefly, an increasing mechanical force was applied
with a probe on the plantar surface of the hind paws
until the animal produced retraction of the paw,
indicating painful perception. Thermal algesimetry test
[20] assesses the time that mice can endure heat ir-
radiation. This test was performed at 28 days once the
mice could sustain their weight on the hind paws.
Histological analyses
Animals used for the functional assessment were sacri-
ficed and perfused with 4% paraformaldehyde in 0.1M
phosphate buffer (PB) at day 28 (n = 16). An 8-mm length
of the spinal cord containing the epicenter of the lesion
was removed and cut into 20-μm-thick sagittal sections
using a cryostat. A subset of sections was used to evaluate
demyelination with Luxol Fast Blue staining (LFB; Sigma-
Aldrich). Briefly, after dehydration, slides were placed in a
1mg/mL LFB solution in 95% ethanol and 0.05% acetic
acid at 37 °C overnight. Then, sections were washed in
95% ethanol and distilled water before being placed into a
0.05% Li2CO3 solution for 3min at room temperature. Fi-
nally, after dehydration, sections were mounted in DPX
mounting medium (Sigma-Aldrich). Myelin sparing of the
three groups of animals was calculated by delineating the
spared LFP-stained tissue area, and the total area, from
images taken at the epicenter of the injury and every
100 μm rostral and caudal to the lesion site using ImageJ
software. Then, the area of residual white matter was
expressed as the percentage with respect to the total area
of the spinal cord section.
For immunohistochemical staining, another subset of
sections was rehydrated in PBS and blocked with 5% FBS
in PBS 0.3Tx for 1 h at room temperature. The spinal cord
sections were then incubated overnight at 4 °C with pri-
mary antibodies against glial fibrillary acidic protein
(GFAP; for astrocytes; 1:1000; AB5804-Millipore), ionized
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calcium-binding adapter molecule 1 (Iba1; for macro-
phages/microglia; 1:500, ab5076-Abcam), and NeuN (for
neurons; 1:75; MAB377x-Millipore, conjugated with Alexa
488). Nuclei were labeled with DAPI staining (1:1000;
D9564-10MG-Sigma). The detection was made with ap-
propriate secondary antibodies conjugated with Alexa
Fluor 594 (A11058 for Goat and A21207 for Rabbit; Invi-
trogen). Finally, after several washes in PBST-Tween 0.1%,
PBS and PB, a coverslip was applied in Fluoromount-G
mounting medium (Southern Biotech). Microphotographs
were taken at × 20, and then, immunoreactivity was ana-
lyzed by measuring the integrated density of a region of
interest (ROI) after defining a threshold for background
correction. The ROI had an area of 0.05mm2 and was
placed on the gray matter and on the white matter. Both
markers were measured from 7 spinal cord sections (sepa-
rated 200 μm) of each animal. Finally, neuronal survival
was assessed by counting the number of neurons located
rostrally and caudally from the epicenter in both ventral
horns. Measurements were performed with ImageJ
software.
Data analysis
Data are expressed as the mean ± standard error of the mean
(SEM), and results were analyzed using GraphPad Prism 7
software. For statistical analysis of cytokine/chemokine RNA
expression, one-way analysis of variance (ANOVA) followed
by Tukey’s post hoc test was performed. For cytokine protein
expression, unpaired t test was performed. Functional test
results were analyzed by two-way ANOVA followed
by Sidak correction for multiple comparisons. Finally,
histological quantification results, including tissue
sparing and immunohistochemistry, were compared
by two-way ANOVA followed by post hoc Tukey’s
multiple comparison test. All differences were consid-
ered statistically significant when p < 0.05.
Results
BET inhibition reduces pro-inflammatory and enhances
anti-inflammatory cytokine production
After SCI, a large number of pro-inflammatory
markers become upregulated. To investigate the effi-
cacy of BET inhibition to modulate the secondary in-
jury response, we monitored the expression of
inflammation-related genes after SCI or in sham mice
treated with the BET inhibitor JQ1 or with vehicle.
As shown in Fig. 1a, at 4 h post-lesion, the expression
of the pro-inflammatory cytokines IL-6, IL-1β, and
TNF-α was significantly reduced in injured mice
treated with JQ1 compared to vehicle-treated mice.
From these cytokines, IL-1β was maintained downreg-
ulated at 72 h post-lesion. We also detected a general
decrease in chemokine levels after JQ1 treatment but
only significantly for CCL2 at 72 h in injured mice
treated with JQ1 compared to vehicle-treated mice
and for CCL2 at 4 h and CX3CR1 at 72 h post-lesion
(Additional file 1: Figure S1B) in sham-treated mice
compared to vehicle-treated animals. These results
validate previous studies [21].
In addition, our results revealed that the anti-
inflammatory effect of JQ1 resides not only on reducing
pro-inflammatory markers but also to upregulate anti-
inflammatory cytokines. JQ1 increased IL-4 and IL-13
mRNA expression at 4 h post-injury and IL-10 levels at
72 h after SCI (Fig. 1b). To note, JQ1 increased IL-4 and
IL-13 also in sham-treated animals (Fig. 1b). To ascer-
tain if the changes observed on cytokine mRNA levels
were traduced on protein levels, we analyzed IL-4, IL-10,
IL-13, and IL-6 protein levels after SCI. IL-4 levels were
undetectable in most of the samples because the detec-
tion levels of the assay were too high for the biological
levels of the protein (data not shown). However, we cor-
roborated the increase of IL-10 and IL-13 in sham and
injured mice treated with JQ1 compared to vehicle-
treated mice (Fig. 2). We also corroborated a decrease of
IL-6 protein expression at 4 h post-injury in JQ1-treated
animals compared to vehicle-treated mice.
In addition, other inflammatory markers related to
macrophage infiltration and microglial activation were
studied. Considering macrophages and microglia, JQ1
treatment after SCI greatly reduced the pro-inflammatory
macrophage marker INOS at 72 h post-lesion
(Additional file 1: Figure S1), although it did not affect the
anti-inflammatory macrophage markers ARG1 and
CD206. Thus, apparently, BET inhibition at the dosage
used did not modify the balance of M1/M2 macrophage
phenotype. However, a higher number of M1/M2 markers
and fluorescence-activated cell sorting (FACS) should be
performed to confirm these results. Besides, astrocyte re-
activity determined by GFAP expression was not affected
by JQ1 administration (Additional file 1: Figure S1B).
Finally, we investigated whether the effects observed
after BET inhibition in SCI could be produced by af-
fecting macrophage reactivity. To simulate the per-
formed in vivo studies, and as a difference with
previous similar studies where macrophages where
pre-treated with JQ1 [15, 21], primary cultures of
BMDMs received a stimulation with LPS during 1 h
and followed or not by JQ1 treatment during 2 h.
Treatment with JQ1 resulted in a reduction of the
pro-inflammatory modulators IL-6 and INOS after
LPS stimulation (Additional file 2: Figure S2). Regard-
ing the anti-inflammatory cytokines IL-4, IL-10, and
IL-13, we found that administration of JQ1 upregu-
lated their transcription. For IL-10 and IL-13, the up-
regulation after JQ1 treatment was found with and
without previous LPS stimulation, and for IL-4, only
without LPS stimulation (Additional file 2: Figure S2).
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Overall, while JQ1 suppressed the expression of key
pro-inflammatory genes, it also produced an early ex-
pression of anti-inflammatory cytokines after SCI. The
changes observed in mRNA levels were concomitant
with changes on protein expression after SCI.
BET inhibition reduces microglia/macrophage reactivity
after SCI
To further study the role of JQ1 in modulating the in-
flammatory response after SCI, we evaluated the expres-
sion of two hallmark markers of inflammation at longer
time periods. Sham or SCI mice were treated with JQ1
or vehicle during 4 or 20 days, and immunoreactivity of
microglia/macrophages and astrocytes was analyzed at
28 days post-injury. Iba1 staining detects both quiescent
and reactive microglia and also infiltrated macrophages.
The long-term JQ1 treatment showed a reduced immu-
noreactivity of Iba1 at the 200 μm rostrally to the lesion
site (Fig. 3a), compared to vehicle treatment. The label-
ing for GFAP revealed that JQ1 did not affect astroglial
reactivity (Fig. 3b). These results are consistent with our
previous RT-qPCR findings at 72 h, showing no signifi-
cant differences in mRNA expression of GFAP after JQ1
administration (Additional file 1: Figure S1B). Therefore,
these results confirm that BET inhibition reduces micro-
glial reactivity without affecting astroglial reactivity.
Fig. 1 BET inhibitor JQ1 reduces expression of pro-inflammatory and increases expression of anti-inflammatory cytokines and chemokines acutely
after SCI. Real-time PCR quantification of a pro-inflammatory cytokines and chemokines at 4 and 72 h after SCI and b anti-inflammatory cytokines
at 4 and 72 h after injury, normalized to the GAPDH levels. N = 4–5 mice per group and time. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001 by
one-way ANOVA followed by Tukey post hoc test. Data are represented as mean ± SEM fold changes of gene expression
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BET inhibition promotes tissue sparing and neuronal
preservation after SCI
The LFB staining results revealed that administration
of JQ1 for 20 days led to significant white matter
sparing in rostral and caudal areas to the injury
epicenter compared to vehicle-treated mice (Fig. 4b).
Besides, the total labeled myelin area was significantly
higher in long-term JQ1-treated mice than in vehicle-
treated mice (Fig. 4c).
The number of surviving neurons in the ventral horn
was counted at the epicenter of the injury and at 200,
400, 600, and 800 μm rostral and caudally. While quanti-
tative analysis of NeuN staining showed that most neu-
rons died at the injury site and surrounding areas in the
three groups of mice, neuron survival was signifi-
cantly increased at different distances from the epi-
center. As it is shown in Fig. 4e, f, neuronal survival
was significantly increased at 600 and 800 μm rostral
from the epicenter, as well as at 800 μm caudal in
long-term JQ1-treated animals compared to vehicle-
and to short-term-treated mice (Fig. 4e, f ). Overall,
histopathological analysis revealed that long-term
treatment of JQ1 conferred significant neuroprotec-
tion after SCI.
BET inhibition enhances functional recovery after SCI
To assess whether BET inhibition had an effect on func-
tional recovery after SCI, locomotion was tested in an
open field and scored with BMS scale. As shown in
Fig. 5a, a gradual recovery of hindlimb locomotion was
observed over the weeks following SCI in all mice. How-
ever, only mice that received JQ1 long-term treatment
(n = 5) showed significant improvement of BMS scores
at 14 and 21 days compared to vehicle-treated animals.
Despite JQ1 administration during the first 4 days after
SCI (n = 6) slightly increased the BMS score, this
Fig. 2 BET inhibitor JQ1 decreases pro-inflammatory and increases anti-inflammatory cytokine protein expression after SCI. The protein levels of
the pro-inflammatory cytokine IL-6 (a) and the anti-inflammatory cytokines IL-10 and IL-13 (b) were quantified via Luminex analysis at 4 and 72 h
after operation. N = 3–4 mice per group and time point. *p < 0.05, **p < 0.01, unpaired t test
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increase was not significantly different from vehicle-
treated mice at any time point.
Finally, neuropathic pain was evaluated with Randall-Selitto
and thermal algesimetry tests (Fig. 5b). Mice treated
with JQ1 for 20 days presented reduced mechanical
allodynia compared to the other groups, with significant
differences at 7 days. The thermal algesimetry test showed
a non-significant increase in the withdrawal threshold to
hot stimulation in JQ1-treated mice.
Thus, BET inhibition enhances functional outcome
and has a transient effect on neuropathic pain after SCI.
Discussion
Although the interest in epigenetics has rapidly in-
creased over the last years, the function of epigenetic
signaling in central nervous system trauma remains
largely unexplored. Thus, the overall goal of this
study was to investigate the therapeutic role of target-
ing the epigenome, specifically BET proteins, after
SCI. For this purpose, we used in vitro and in vivo
approaches to study the effect of the BET inhibitor
JQ1 on inflammation, neuroprotection, functional re-
covery, and ultimately on neuropathic pain. The
Fig. 3 JQ1 treatment reduces macrophage and microglia reactivity after SCI. a Iba1 and b GFAP immunoreactivity quantification at 800 μm
rostrally and caudally from the injury epicenter. Histograms represent the mean integrated density ± SEM quantified in gray (left) and white (right)
matter in the ventral zone of the spinal cord sections. Representative images of Iba1 (a) and GFAP (b) at 200 and 400 μm, respectively, rostral to
the epicenter are shown. Scale bar = 100 μm. N = 4–5 mice per group. *p < 0.05 compared to vehicle-treated animals and #p < 0.05 compared to
short-term-treated animals as calculated by two-way ANOVA with Tukey post hoc test
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results of the present study indicate that inhibition of
BET proteins reduces inflammation and may repre-
sent a novel therapeutic target for SCI. We have ob-
served that JQ1 decreased pro-inflammatory and
increased anti-inflammatory cytokine expression
acutely after SCI. We used JQ1 treatment at two dif-
ferent time regimes and observed that the prolonged
treatment with JQ1 reduced the inflammatory re-
sponse and increased neuroprotection. Altogether,
these neuroimmune outcomes were associated with
an improvement of functional recovery and reduction
in neuropathic pain. Overall, the results of the
present study highlight the importance of epigenetic
regulation on inflammation after SCI.
Effects of BET inhibition on the inflammatory response
One of the major findings of the present study is that
BET inhibition, besides reducing pro-inflammatory cyto-
kine expression, which had been previously described
[15, 21], enhances anti-inflammatory cytokine produc-
tion. This effect was observed after SCI and in a primary
culture of bone marrow-derived macrophages. BET pro-
teins are epigenetic readers, i.e., they read the acetylated
residues in histones located in specific promoters, and
Fig. 4 BET inhibition increases tissue preservation and neuronal survival after SCI. a, b Quantification of the percentage of white matter sparing,
with respect to the total area of the spinal cord, from the injury epicenter up to 1000 μm rostral and caudally. c Percentage of total spared white
matter in 2-mm spinal cord samples from different mouse groups. d Representative micrographs of sections stained with LFB at 300 μm rostral to
the epicenter from vehicle-treated, JQ1 short-term-treated and JQ1 long-term-treated animals. e Quantification of ventral horn neuron survival
from the injury epicenter to 800 μm rostral and caudally. f Representative micrographs showing sparing ventral horn neurons from vehicle-
treated, JQ1 short-term-treated and JQ1 long-term-treated animals at 600 μm rostral to the lesion site. N = 4–5 mice per group. Scale bars, 500 μm
(d, f). *p < 0.05, ***p < 0.005, and ****p < 0.001 compared to vehicle-treated group and #p < 0.05 and ####p < 0.001 compared to short-term-treated
group as calculated by two-way ANOVA with Tukey post hoc test. Data are represented as mean ± SEM
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promote gene expression. Thus, its inhibition commonly
reduces gene expression. The reduction of these
inflammatory-related genes, which are mediated by NF-
kB signaling, can be explained by the disruption of the
normal functioning of BET proteins by JQ1 treatment
during an inflammatory response [22, 23]. However, mo-
lecular mechanisms for increasing anti-inflammatory
cytokine production after BET inhibition are elusive.
This effect may be indirect. However, BET protein BRD4
can confer transcriptional repression by interacting with
several repressive complexes [24–26]. Thus, it might be
possible that BET inhibition treatment produces
chromatin release of these complexes and triggers
promoter de-repression as suggested previously [25],
inducing increases of anti-inflammatory cytokine pro-
duction. However, further experiments should be per-
formed to decipher the molecular events undergoing
these effects.
The importance of macrophages and microglia in SCI
lies in their influence to exacerbate inflammation as well
as repair. These opposite actions are possible through
macrophage/microglia polarization [5]. The raised levels
of the anti-inflammatory cytokines IL-4, IL-10, and IL-
13 observed after JQ1 treatment are particularly interest-
ing since many studies have highlighted their relevance
in inducing an alternative activation to macrophages,
which is linked to SCI recovery [1, 27, 28]. However, we
found that the enhancement in anti-inflammatory cyto-
kines could reduce the expression of the M1 marker
iNOS but could not increase M2 markers (ARG1 and
CD206), and thus, it might not affect the switch of mac-
rophages into an anti-inflammatory phenotype. Accord-
ingly to literature, this result could be explained because
not all of the M1 and M2 markers seem to change ex-
pression in a coordinated fashion after SCI [5]. Never-
theless, a higher number of M1/M2 markers and
fluorescence-activated cell sorting (FACS) of macro-
phages and microglia harvested from the injured spinal
cord would provide a better understanding of the
changes in macrophage phenotype after JQ1. Besides, it
might be possible also that the dosage or timing of the
treatment was not sufficient to induce a substantial in-
crease of IL-4 to observe these effects. In fact, we were
not able to detect IL-4 protein with the cytokine protein
expression assay (data not shown). We cannot affirm
that BET inhibition did not enhance IL-4 production,
since the detection range of the assay was higher than
the protein biological levels. However, these levels are
below those needed to produce a shift towards an M2
phenotype.
Fig. 5 BET inhibition treatment increases functional outcome and reduces neuropathic pain after SCI. a BMS locomotion score along 28 days
post-contusion. b Mechanical algesimetry results (left), expressed as percentage of baseline values, during follow-up, and thermal algesimetry
results (right), expressed as absolute values in seconds, recorded at 28 days post-operation. N = 5–6 mice per group; *p < 0.05 as calculated by
two-way ANOVA followed by Sidak correction for the multiple comparisons. Data are represented as mean ± SEM
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Effects of BET inhibition on neuroprotection and
functional recovery
A challenge for researchers who work in the CNS
trauma field is to control the cross-talk between the
immune and nervous system to prevent neurodegen-
eration and tissue loss. In the current study, we ob-
served that JQ1 can promote neuroprotection, tissue
preservation, and locomotion improvement. These
beneficial effects may be attributed to the role of JQ1
modulating inflammation. The observed reduction in
pro-inflammatory cytokines and also the increase of
anti-inflammatory cytokines may overcome the neuro-
toxic environment of the acute phase of SCI, which
eventually culminates in neuronal and oligodendrocyte
death as well as tissue loss. In the end, these benefi-
cial outcomes might improve functional recovery.
This conclusion is formed in view of the substantial
literature related to the neurotoxic effects of TNF-α and
IL-1β and the neuroprotective effects of IL-4 and IL-10
[5, 29]. Regarding pro-inflammatory cytokines, it has
been described that blocking TNF-α and IL-1β confers
neuroprotection in SCI and stroke models [8]. For in-
stance, it has been reported that the genetic or pharma-
cological inhibition of TNF-α reduces inflammation,
injured tissue, and the number of apoptotic cells which
overall ameliorate the recovery of limb function [30].
Considering anti-inflammatory cytokines, it has been
demonstrated that a treatment of IL-4 reduces tissue
damage and locomotion impairment after SCI [28].
Despite our LFB staining revealed an enhanced tissue
preservation, this fact cannot be directly linked to a pro-
tective action against oligodendrocyte death. Thus, fu-
ture histological procedures will be performed to analyze
the effects of JQ1 treatment on oligodendrocytes. How-
ever, we could observe enhanced neuronal survival,
demonstrating a neuroprotective effect of JQ1 on these
cells after SCI, probably due by the decreased cytotoxic
environment produced by JQ1 treatment. This preserva-
tion was statistically significant in areas adjacent to the
injury epicenter.
Our studies demonstrate an acute effect of BET in-
hibition by reducing pro-inflammatory and increasing
anti-inflammatory cytokine/chemokine levels after
SCI. However, neuroprotection was observed only
after a prolonged treatment during 20 days and not
after a short treatment of 4 days, timing when most
of the enhanced cytokines/chemokines return to con-
trol levels after SCI [8]. Thus, other chronic effects of
BET inhibition may also account for these mecha-
nisms. It may be possible that a sustained increase of
anti-inflammatory cytokines could promote prolonged
neuroprotective/regenerative effects. In fact, IL-4, IL-
10, and IL-13 high levels promote enhanced axonal
regeneration [31, 32], promote neuroprotection after
SCI [29, 33], and reduce demyelination in multiple
sclerosis [34]. Besides, it is reported that BET pro-
teins play a role in most of neuronal types [21, 35].
Therefore, further studies should be performed ana-
lyzing the role of BET inhibition in neuroprotection,
axonal regeneration, and demyelination after a pro-
longed treatment.
Effects of BET inhibition on neuropathic pain
Functional assessment of neuropathic pain showed pres-
ervation of the mechanical threshold at 7 days post-
injury. There are 2 main mechanisms thought to con-
tribute to hyperexcitability and therefore to the ontogeny
of neuropathic pain (reviewed in [36]). One is the release
of neuromodulators such as pro-inflammatory cytokines
and chemokines, which enhance neuronal excitability.
The other one is the altered expression, trafficking, and
functioning of receptors and ion channels expressed by
primary sensory neurons. Thus, probably BET treatment
is only effective on reducing pro-inflammatory media-
tors, such as TNF-α, CCL2, and CX3CR1, which are dir-
ectly implicated in neuropathic pain. Of interest, both
CCR2 and CX3CR1-knockout mice exhibit reduced
neuropathic pain [37]. A combination with any other
epigenetic treatment that regulates gene expression in
primary sensory neurons could produce a prolonged ef-
fect on neuropathic pain.
We and several authors report beneficial effects of
BET inhibition reducing tumor growth [38–40], in-
creasing brain plasticity [41], promoting neuroprotec-
tion [42], and decreasing inflammation in several
pathologies [43, 44]. However, higher doses of JQ1
can block memory formation [35] or produce lymph-
oid and hematopoietic toxicity in mice [45] and can
even enhance undesirable virus replication [46, 47]. In
fact, we observed that doubling the dose of the com-
pound produced a decrease in body weight and
mouse death after SCI (data not shown). Therefore,
further studies carefully dissecting the dosage, analyz-
ing the molecular mechanisms of action, and deter-
mining undesirable effects of BET inhibitors should
be performed to find the balance between beneficial
and detrimental effects of BET inhibition in each
pathological condition and be able to progress to-
wards clinical trials [48].
Conclusions
This work elucidates an epigenetic mechanism which
contributes to the pathogenesis of inflammation and
SCI. Although BET inhibition has been previously re-
ported to have an anti-inflammatory effect after SCI
[21], a beneficial outcome of BET inhibition treatment
after SCI has never been reported before. Thus, the
present study demonstrates for the first time that
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BET proteins are a target for the treatment of SCI,
promoting neuroprotection, behavioral recovery, and
decreased neuropathic pain. Neuroinflammation is a
common feature of several human neurodegenerative
diseases. Therefore, the discoveries from the present
project may provide therapeutic innovation for many
other pathologies, increasing the translational impact
of the present study.
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Additional file 1: JQ1 treatment modifies the M1 marker INOS but do
not modify markers of M2 macrophage phenotype, or astrocyte reactivity.
Real-time PCR quantification of (A) M1 and M2 markers and (B) macro-
phage and glial markers at 4 and 72 h after SCI, normalized to the
GAPDH levels. N =3-4 mice/group. *p < 0.05, ***p < 0.005, as calculated
by one-way ANOVA followed by Tukey post-hoc test. Data are repre-
sented as mean ± SEM fold changes of gene expression. (TIF 1771 kb)
Additional file 2: BET inhibition affects macrophage reactivity in vitro.
Real-time PCR quantification of (A) pro-inflammatory and (B) anti-
inflammatory cytokines at 3 h after LPS (100 ng/ml) stimulation, normal-
ized to the GAPDH levels. Experiments were repeated 3 independent
times. *p < 0.05, **p < 0.01, ***p< 0.005, as calculated by one-way ANOVA
followed by Tukey post-hoc test. Data are represented as mean ± SEM
fold changes of gene expression. (TIF 1378 kb)
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